

Dietary nitrate supplementation alters the oral microbiome but does not improve the vascular responses to an acute nitrate dose

Running Title: Beetroot juice improves markers of oral health

Mia Burleigh¹, Luke Liddle¹, David J. Muggeridge², Christopher Monaghan¹, Nicholas Sculthorpe¹, John Butcher³, Fiona Henriquez¹, Chris Easton¹

¹Institute of Clinical Health and Exercise Sciences, University of the West of Scotland, Blantyre, G72 0LH, Scotland.

²Institute of Health Research & Innovation, Division of Biomedical Science, University of the Highlands and Islands, Inverness, IV2 3JH, Scotland.

³Department of Life Sciences, School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, G4 0BA, Scotland.

Corresponding author: Dr Chris Easton
University of the West of Scotland
Blantyre
G72 0LH
Scotland
T: 01698 283 100
E: chris.easton@uws.ac.uk

Abstract

Nitrate (NO_3^-) contained in food and beverages can transiently increase nitric oxide (NO) availability following a stepwise reduction to nitrite (NO_2^-) by commensal bacteria in the oral cavity. We tested the hypothesis that regular ingestion of dietary NO_3^- would influence the oral microbiome, the capacity to reduce NO_3^- to NO_2^- in saliva, and the vascular responses to an acute dose of NO_3^- . The abundance of bacterial species on the tongue, the availability of NO markers, and vascular function were assessed in 11 healthy males before and after 7 days of supplementation with NO_3^- -rich beetroot juice and a NO_3^- -depleted placebo. As expected, saliva and plasma NO_2^- and NO_3^- were significantly elevated after NO_3^- supplementation (all $P < 0.05$) but not placebo. We found that NO_3^- supplementation increased salivary pH (7.13 ± 0.54 to 7.39 ± 0.68 , $P = 0.043$) and altered the abundance of some bacteria previously implicated in NO_3^- reduction: *Neisseria* (from $2\% \pm 3\%$ to $9\% \pm 5\%$, $P < 0.001$), *Prevotella* (from $34\% \pm 17\%$ to $23\% \pm 11\%$, $P = 0.001$) and *Actinomyces* (from $1\% \pm 1\%$ to $0.5\% \pm 0.4\%$). Despite these alterations to the oral microbiota, an acute dose of NO_3^- increased salivary and plasma NO_2^- , reduced systolic blood pressure and increased the response to flow mediated dilation to a similar extent before and after 7 days of supplementation ($P > 0.05$). Our study establishes that supplementing the diet with NO_3^- for a sustained period can alter the oral environment in favour of health but does not impact the response to an acute NO_3^- dose. Acute ingestion of NO_3^- results in transient improvements in vascular function but the dietary induced adaptations to the oral bacteria did not enhance these effects.

1 **1. Introduction**

2 The metabolic and immunological activity of the hundreds of species of bacteria that live
3 in and on the human body can directly influence biological function and health. The
4 presence of dysbiotic microbiomes has been linked to various pathologies which include
5 allergies, asthma, inflammatory diseases, obesity, cardiovascular disease and the
6 metabolic syndrome [1]. Conversely, certain commensal microbes from the genera
7 *Granulicatella*, *Actinomyces*, *Veillonella*, *Prevotella*, *Neisseria*, *Haemophilus*, and
8 *Rothia* are thought to contribute to the generation of nitric oxide (NO) [2,3]. Myriad
9 biological processes are critically dependent on NO, including host defence via
10 antimicrobial actions [4], regulation of mucosal blood flow and mucus generation [5],
11 regulation of smooth muscle contraction [6,7], cerebral blood flow [8], glucose
12 homeostasis [9], and mitochondrial function [10].

13
14 Inorganic nitrate (NO_3^-) is regularly consumed in the diet through foods such as beetroot
15 and green leafy vegetables [11]. NO_3^- enters the gastrointestinal tract where it is rapidly
16 absorbed, enters the circulation, and is secreted in the saliva [12]. Here, it can interact
17 with bacteria concentrated on the dorsal surface of the tongue [2]. Some species of
18 bacteria use the NO_3^- as an alternative electron acceptor which reduces the ion to nitrite
19 (NO_2^-). The NO_2^- in saliva is then swallowed and enters the stomach. In the acidic
20 environment of the stomach, NO_2^- forms nitrous acid which is further converted to
21 nitrosating species and subsequently to bioactive NO in the presence of ascorbic acid
22 [13]. This pathway is known as the enterosalivary NO_3^- - NO_2^- -NO pathway [14].
23 Alternatively, NO_3^- and NO_2^- can be stored in the blood and tissues for conversion to NO
24 when endogenous production of NO via the NO synthases (NOS) is limited [15]. The
25 ingestion of NO_3^- -rich beetroot juice has been shown to increase the availability of NO
26 and improve exercise performance in simulated altitude [16], reduce blood pressure (BP)
27 [17], enhance endothelial function [6], and is protective against models of
28 ischemia/reperfusion injury [18]. On the other hand, a recent meta-analysis reported that
29 NO_3^- supplementation has only small and trivial effects on exercise performance [19].

31 We have shown previously that individuals with a higher abundance of NO₃⁻ reducing
32 bacteria were able to generate more salivary NO₂⁻ and at a faster rate following the
33 ingestion of NO₃⁻-rich beetroot juice [20]. In contrast, when the enzymatic activity of
34 bacteria in the mouth is disrupted by antibiotic use or rinsing the mouth with anti-bacterial
35 mouthwash, the BP lowering effects of NO₃⁻ are abolished [14,21–23]. Oral microbiota
36 live in regulated communities [24] in which they can use quorum sensing and potassium
37 ion channel mediated electrical signalling to communicate and rapidly respond to
38 environmental stimuli [25]. This allows them to maintain the functional and structural
39 integrity of their ecosystems via replication and alterations to their gene expression
40 [26,27]. The composition of an individual's diet can rapidly alter the conditions of the
41 oral cavity by varying substrate availability for commensal bacteria and environmental
42 factors such as pH.

43

44 Given the malleability of the oral environment, previous research has sought to determine
45 the effects of dietary NO₃⁻ supplementation on the oral microbiome with a view to
46 optimising the enterosalivary pathway to improve health. In an animal model, Hyde and
47 colleagues [28] found that the abundance of the NO₃⁻ reducer *Haemophilus*
48 *parainfluenzae* increased following NaNO₃⁻ supplementation. In hypercholesteremia
49 patients, Velmurugan et al. (2016) reported that 6 weeks of beetroot juice increased the
50 abundance of *Neisseria* and *Rothia*. Recently, Vanhatalo and colleagues [30] expanded
51 these findings in healthy young and older adults showing that 10 days of beetroot juice
52 supplementation increased the abundance of *Neisseria* and *Rothia* with concomitant
53 reductions in *Prevotella* and *Veillonella*.

54

55 Whilst it has been shown that NO₃⁻ supplementation can alter the microbiome, it is
56 presently unclear how this impacts the capacity to reduce NO₃⁻ following a dietary load.
57 Based on our previous findings [19], one may hypothesise that an increased abundance
58 of NO₃⁻-reducing bacteria will increase salivary and plasma NO₂⁻ production and enhance
59 the acute vascular responses to dietary NO₃⁻. Therefore, our primary objective was to
60 assess the effects of 7 days of beetroot juice supplementation on the abundance of NO₃⁻-
61 reducing bacteria in the oral cavity and assess the impact of these changes on NO

62 metabolites and markers of vascular function in healthy adults immediately following a
63 NO_3^- dose.

64

65 **2. Methods**

66 ***2.1. Ethical approval***

67 The study was approved by the School of Science and Sport Ethics Committee at The
68 University of the West of Scotland. All procedures described were conducted in
69 accordance with the Declaration of Helsinki 1974 and its later amendments.

70

71 ***2.2. Participants***

72 Eleven healthy males (age 30 ± 7 years, stature 179 ± 7 cm, and body mass 86.9 ± 14.1
73 kg) volunteered and provided written informed consent prior to participating in the study.
74 All participants were in good cardiovascular and oral health and did not report any use of
75 antibacterial mouthwash or antibiotics for at least 6 months prior to study
76 commencement. They were free from non-prescription medication including those known
77 to interfere with stomach acid production and were not taking any prescribed medication.
78 Health status was confirmed by completion of a medical questionnaire and The World
79 Health Organisation's oral health questionnaire was used to ascertain oral health status.

80

81 ***2.3. Experimental Design***

82 Participants were required to attend the laboratory on four separate occasions for this
83 placebo-controlled, single blind randomised crossover study. The study comprised two
84 separate 7 day dietary supplementation phases, each preceded by a baseline trial (day 0)
85 and completed with a post-supplementation trial (day 8). In one arm of the study,
86 participants ingested 70 ml of NO_3^- -rich beetroot juice (~ 6.2 mmol NO_3^-) (Pro-Elite
87 Shots, James White Drinks Ltd., Suffolk, England) in the morning and 70 ml in the
88 evening. In the other arm, participants ingested the same volume of NO_3^- -depleted
89 beetroot juice (Placebo shots, James White Drinks Ltd., Suffolk, England). Both versions

90 of the beetroot juice were identical in taste and appearance. The supplementation phases
91 were separated by a prolonged washout period (4 weeks) as it is currently unclear how
92 long it takes the oral microbiome to return to baseline following modification via dietary
93 NO_3^- . All experimental trials were identical with the exception that an acute NO_3^-
94 response test was carried out on days 0 and 8 of the NO_3^- -rich beetroot juice phase but
95 not the placebo phase. The decision to exclude this protocol from the placebo phase was
96 based on the premise that the oral microbiome is highly responsive to dietary stimuli
97 [31,32] and a large amount of NO_3^- on day 0 might have altered the post-supplementation
98 markers in the placebo phase. Participants were informed that the acute NO_3^- response
99 test would be implemented in one of the two testing arms and they were not aware that
100 this was only in the NO_3^- -rich phase.

101

102 **2.4. Procedures**

103 Prior to the first trial, participants were briefed on procedures and were provided with a
104 food diary in which they recorded all foods consumed 7 days prior to the trial and during
105 the supplementation period. This diary was used to replicate diet in the week preceding
106 the second supplementation phase. Participants arrived at the laboratory on the morning
107 of each trial in a fasted and euhydrated state after consuming 500 ml of water 1 h before
108 each trial. Participants were instructed to avoid strenuous exercise for 24 h and caffeine
109 for 12 h before each trial. On the morning of each trial, participants were requested not to
110 brush their teeth and tongue or chew gum. They were also requested not to use mouthwash
111 throughout the study and report any changes in health status. Participants provided
112 assurance of their compliance with these instructions via completion of a checklist on
113 each visit.

114

115 Anthropometric characteristics were recorded at the beginning of each visit using
116 conventional methods. Following this, participants lay supine for the remainder of the
117 experiment. The posterior dorsal surface of the tongue was swabbed for 1 min with a
118 sterile Hydraflock swab (Puritan HydraFlock Swabs, Puritan Diagnostics LLC, Guilford,
119 Maine, USA.). This area of the tongue is known to harbour NO_3^- reducing bacteria and is

120 the area of the oral cavity in which the majority of NO₃⁻ reduction activity occurs [2]. The
121 swabs were transferred to transport tubes containing 0.85 ml of buffered sterile saline and
122 0.15 ml of glycerol and subsequently frozen and stored at -80 °C

123

124 No further measurements were collected for 30 min to ensure plasma [NO₂⁻] had
125 stabilised following the change in body posture [33]. Subsequently, heart rate (HR) was
126 measured via telemetry (Polar Electro, Oy, Finland) and systolic BP (SBP) and diastolic
127 BP (DBP) were recorded in triplicate using an automated device (Orman M6, Intelli-
128 Sense. Hoofddorp, Netherlands). Mean arterial pressure (MAP) was calculated using the
129 following equation:

130

$$131 \text{ MAP} = (2 \times \text{DBP} + \text{SBP}) / 3$$

132

133 Endothelial function of the brachial artery was then assessed by flow mediated dilation
134 (FMD), described in detail below. Venous blood was collected via venepuncture from the
135 forearm in 4 ml aliquots in vacutainer tubes containing ethylenediaminetetraacetic acid
136 (BD vacutainer K2E 7.2mg, Plymouth, U.K.). Samples of whole blood were immediately
137 centrifuged for 10 min at 4000 rpm at 4°C (Harrier 18/80, Henderson Biomedical. UK)
138 following collection. Samples of unstimulated saliva were concurrently collected via an
139 oral swab (Saliva Bio Oral Swab (SOS) Salimetrics, Pennsylvania, USA) placed under
140 the tongue for 3 min. Swabs were transferred to a collection tube (Sartedt,
141 Aktiengesellschaft & Co, Numbrecht, Germany) and centrifuged at 4000 rpm for 10 min
142 at 4°C (Harrier 18/80, Henderson Biomedical. UK). Following centrifugation, the
143 samples of plasma and saliva were immediately stored at -80°C for later analysis of NO₃⁻
144 and NO₂⁻ content via ozone-based chemiluminescence. The swabs were analysed and
145 found to contain negligible levels NO₃⁻ and NO₂⁻.

146

147

148

149 *2.4.1. Acute Nitrate Response Test*

150 On days 0 and 8 of the NO₃⁻-rich supplementation phase, participants completed an acute
151 NO₃⁻ response test following completion of the procedures described above. In this
152 component, participants ingested 2 x 70 ml of NO₃⁻-rich beetroot juice (~12.4 mmol NO₃⁻
153 , James White Drinks Ltd., Suffolk, England). A sample of saliva was collected 90 min
154 after ingestion followed by a blood sample, and measurements of BP and FMD at 150
155 min. This protocol facilitated the comparison of NO₃⁻ metabolism before and after the
156 expected alteration of the oral microbiome.

157

158 *2.4.2. Flow Mediated Dilation*

159 On the contralateral arm to that used for blood collection, the endothelium-dependent
160 vascular responses of the brachial artery were assessed by high-resolution ultrasound
161 imaging and automated vessel diameter measurements. Ultrasound images were recorded
162 using a Vivid 7 ultrasound machine (GE Vingmed, Horten, Norway) with a L10 11MHz
163 linear array transducer. A straight, non-branching segment of the brachial artery above
164 the antecubital fossa was identified and imaged in the longitudinal plane with
165 simultaneous capture of blood flow gated pulse wave using Doppler imaging. The
166 Doppler gate was set to encompass the majority of the width of the artery and was angle
167 corrected at 60°. The brachial artery diameter was initially recorded for 1 min (baseline).
168 A cuff on the upper forearm (distal to the imaging site) was then inflated to supra-systolic
169 pressure (220 mmHg) for 5 min using a rapid cuff inflator (Hockansen, Bellevue, WA,
170 USA). The cuff was then rapidly deflated and the same segment of the brachial artery was
171 imaged for 5 min with concurrent measurement of blood flow.

172

173 Automatic edge detection software (Brachial Analyzer, Medical Imaging Applications
174 LLC, Coralville) was used to measure the diameter of the brachial artery and blood flow
175 using the envelope of the Doppler spectral traces and to calculate hyperaemic shear. The
176 area under the curve for the hyperaemic shear data was then measured up to the point of
177 maximal arterial dilation using the Reimann sum technique. The change in brachial artery
178 diameter was calculated using a 3 s average and expressed as percentage change from

179 baseline. As FMD changes are partly dependent upon vessel diameter, the absolute
180 diameter changes were also calculated. The coefficient of variation (CV) for the FMD
181 measurement in our laboratory is 5.6%.

182

183 *2.4.3. Analysis of saliva and plasma samples*

184 The pH of saliva samples was measured in duplicate with a circular electrode pH-meter
185 1140 Mettler Toledo (Greisensee, Switzerland) which has a precision of 0.01 pH unit.
186 The measured pH value was not accepted until an unchanged pH value was observed for
187 a period of at least 7 s. Calibration of the pH meter was performed before analysis and
188 after every 10 samples using buffers with known pH (4.01 and 7.00). The electrode was
189 rinsed with deionised water between samples.

190

191 For the analysis of plasma and saliva $[\text{NO}_2^-]$, tri-iodide reagent (2.5 ml glacial acetic acid,
192 0.5 ml of 18 Ω deionised water, and 25 mg sodium iodide) was placed in a glass purge
193 vessel heated to 50°C and connected to a NO analyser (Sievers NOA 280i, Analytix, UK).
194 A standard curve was created by injecting 100 μL of NO_2^- solutions at various
195 concentrations up to 1000 nM (plasma) and 3000 nM (saliva). Samples were thawed in a
196 water bath at 37°C and 100 μL of the sample was injected immediately into the purge
197 vessel in duplicate. Saliva samples were initially diluted with deionised water at a ratio
198 of 1:100 before injection. The NO_2^- content was calculated via the area under the curve
199 using Origin software (version 7.1).

200

201 For the analysis of $[\text{NO}_3^-]$, vanadium reagent (24 mg of vanadium tri-chloride and 3 ml
202 of 1 M hydrochloric acid) was placed into the purge vessel and heated to 90°C. A standard
203 curve was created by injecting 10-25 μL NO_3^- solutions at concentrations up to 100 μM
204 for both plasma and saliva. Plasma samples were initially de-proteinised using 1 M zinc
205 sulfate (ZnSO_4) at 1:10 w/v and 1 M sodium hydroxide (NaOH) at a 1:1 ratio. 200 μL of
206 plasma was added to 400 μL of ZnSO_4 and 400 μL of NaOH . Each sample was vortexed
207 for 30 s prior to being centrifuged for 5 min at 4000 rpm and the supernatant was injected
208 into the purge vessel. The NO_3^- concentration was calculated as previously described for
209 NO_2^- .

210 2.4.4. 16S Metagenomic Sequencing

211 DNA from the tongue swab samples was isolated (Illumina MasterPure kit, Epicentre,
212 Madison, WI, USA) before shipping to a commercial analysis centre (Omega Bioservices,
213 Norcross, GA, USA). The libraries were prepared using an Illumina 16S Metagenomic
214 Sequencing kit (Illumina, Inc., San Diego, CA, USA) according to the manufacturer`s
215 protocol. The V3-V4 region of the bacterial 16S rRNA gene sequences were amplified
216 using the primer pair containing the gene-specific sequences and Illumina adapter
217 overhang nucleotide sequences. Samples were prepared by combining 12.5 ng of the
218 DNA sample with 12.5 µL of 2x KAPA HiFi HotStart ReadyMix (Kapa
219 Biosystems, Wilmington, MA) and 5 µL of 1 µM of each primer. The full-length primer
220 sequences were: 16S Amplicon PCR Forward Primer (5'-
221 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG)
222 and 16S Amplicon PCR Reverse Primer (5'-
223 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTA
224 ATCC).

225

226 Samples were initially subjected to denaturation at 95°C for 3 min followed by 25 x 30 s
227 cycles of denaturation (95°C), annealing (55°C) and extension (72°C), and a final
228 elongation of 5 min at 72°C. The PCR product was cleaned up from the reaction mix with
229 Mag-Bind RxnPure Plus magnetic beads (Omega Bio-tek, Norcross, GA). A second index
230 PCR amplification, used to incorporate barcodes and sequencing adapters into the final
231 PCR product, was performed in 25 µL reactions, using the same master mix conditions
232 as described above. Samples were further subjected to 8 x 30 s cycles of denaturation
233 (95°C), annealing (55°C), and extension (72°C) followed by a 5 min elongation step at
234 72°C. The library of approximately 600 bases in size was checked using an Agilent 2200
235 TapeStation and quantified using QuantiFluor dsDNA System (Promega). Following this,
236 libraries were normalised, pooled and sequenced on the MiSeq (Illumina, San Diego, CA)
237 using the 2 x 300 bp paired-end read setting.

238

239

240 2.4.5. 16s rRNA Gene Data Analysis

241 Quality filtered data received from the sequencing centre were interrogated using the
242 Qiime 1.8 database [34]. Sequences were clustered *de novo* and binned into operational
243 taxonomic units (OTU) based on 99% identity. Taxonomy was assigned using the RDP
244 classifier trained to the GreenGenes database (October 2013 release). After removal of
245 singleton reads from the dataset, 964,418 sequences remained with an average of 21918
246 sequences per sample. Alpha diversity metrics were calculated by subsampling the OTU
247 table ten times at a depth of 1420 reads per sample. The mean values across the ten
248 subsampled OTU tables were used in diversity calculations. Only species of NO₃⁻-
249 reducing bacteria that comprised at least 0.01% of the total oral microbiome were
250 included in the subsequent statistical analyses.

251

252 2.5. Statistics

253 The Statistical Package for the Social Sciences (SPSS Version 24.0. Armonk, NY: IBM
254 Corp) was used for statistical analysis. GraphPad Prism version 5 (GraphPad Software
255 Inc., San Diego, USA) was used to create the figures. The distributions of data were
256 assessed using the Shapiro Wilk test and non-parametric tests were used where data were
257 not normally distributed. A two-way repeated measures analysis of variance (ANOVA)
258 was used to assess the main effects of time (pre- (day 0) and post-supplementation (day
259 8)) and study arm (placebo vs NO₃⁻) and interaction effects on plasma and salivary NO₃⁻
260 and NO₂⁻, pH, BP measurements, and the abundance of NO₃⁻-reducing bacteria. For the
261 acute NO₃⁻-response tests, a two factor ANOVA was used to determine the main effects
262 of time (pre- (day 0) and post-supplementation (day 8)) and measurement (before and
263 after the acute ingestion of beetroot juice) and their interaction on plasma and salivary
264 NO₃⁻ and NO₂⁻, pH, and BP measurements. *Post-hoc* analysis was conducted following a
265 significant main effect or interaction using paired samples t-tests with Bonferroni
266 correction for multiple pairwise comparisons. The alpha level for declaring statistical
267 significance was set at $P \leq 0.05$. Data are presented as mean \pm standard deviation (SD)
268 unless otherwise stated. Probability values are expressed with 95% confidence intervals
269 (95% CI) where appropriate.

270 3. Results

271 3.1. Impact of 7 days of NO_3^- supplementation on bacterial abundance

272 Alpha diversity data are presented in Table 1. The Shannon diversity index and the
273 number of observed OTU's were similar between study arms and did not change
274 following supplementation (all $P > 0.05$). The abundance of the most prevalent ($>1\%$
275 relative abundance) at each measurement point are included in the supplementary data.

276


277 The most abundant five phyla on the tongue across all four visits were Bacteroidetes (38.1
278 $\pm 3.5\%$), Firmicutes ($30.7 \pm 2.3\%$), Fusobacteria ($12.1 \pm 1.4\%$), Proteobacteria ($11.3 \pm$
279 4.6%), and Actinobacteria ($3.7 \pm 0.6\%$). The relative abundances of Bacteroidetes,
280 Firmicutes, Fusobacteria, and Actinobacteria did not change after NO_3^- or placebo
281 supplementation and did not differ at baseline between study arms (all $P > 0.05$). There
282 was a main effect of 'time' ($P = 0.009$), and 'study arm' ($P = 0.04$) on Proteobacteria.
283 The abundance of Proteobacteria significantly increased following NO_3^- supplementation
284 ($P = 0.011$, 95% CI 2.5% - 15.5%) but not placebo ($P > 0.05$). Proteobacteria did not
285 differ at baseline between study arms ($P > 0.05$). The relative abundance of the phyla at
286 each measurement point are included as supplementary data.

287

288 Dietary NO_3^- supplementation altered the abundance of four genera of bacteria on the
289 tongue (Table 1). Dietary NO_3^- supplementation reduced the relative abundance of
290 *Prevotella* ($P = 0.021$, 95% CI 2.1% – 20.3%), *Streptococcus* ($P = 0.029$, 95% CI 0.4%
291 – 6.1%) and *Actinomyces* ($P = 0.028$, 95% CI 0.1% - 1.1%) with no change following
292 placebo and no differences at baseline between study arms (all $P > 0.05$). The abundance
293 of *Neisseria* increased from baseline in both the NO_3^- supplementation arm ($P < 0.001$,
294 95% CI 4.4 – 9.5%) and the placebo ($P = 0.006$, 95% CI 0.9% – 4.2%). There were no
295 differences at baseline between study arms ($P > 0.05$). The magnitude of the increase in
296 *Neisseria* was greater in the NO_3^- supplementation arm compared to the placebo ($P =$
297 0.001 , 95% CI 2.9% - 8%).

298

299 At species level, there were significant effects of time and an arm*time interaction effect
300 on the relative abundance of *Prevotella melaninogenica* ($P = 0.03$, $P = 0.01$) and
301 *Neisseria subflava* (Fig. 1). There was also a significant main effect of ‘time’ on
302 *Actinomyces hyovaginalis* ($P = 0.01$). The relative abundance of *Prevotella*
303 *melaninogenica* and *Actinomyces hyovaginalis* were lower after 7 days of NO_3^-
304 supplementation compared to pre-supplementation ($P = 0.001$, 95% CI 6.7% – 20% and
305 $P = 0.002$, 95% CI 0.1% - 0.3% respectively) and at both time points in the placebo arm
306 (both $P < 0.005$). The relative abundance of *Prevotella melaninogenica* and *Actinomyces*
307 *hyovaginalis* did not differ at baseline between study arms and were unaltered by 7 days
308 of placebo supplementation (all $P > 0.05$). The relative abundance of *Neisseria subflava*
309 increased from baseline after 7 days of NO_3^- supplementation ($P < 0.001$, 95% CI 3.5%
310 – 8.6%) and also after 7 days of placebo ($P = 0.008$, 95% CI 0.7% – 3.6%). The magnitude
311 of the increase in *Neisseria subflava* was greater in the NO_3^- supplementation arm
312 compared to the placebo ($P = 0.001$ 95% CI 2.3% - 7.3%). There was no difference in the
313 relative abundance of *Neisseria subflava* at baseline between the NO_3^- and placebo
314 supplementation arms ($P > 0.05$). There were no other differences in any other species or
315 genera of bacteria that are thought to contribute to NO_3^- reduction (all $P > 0.05$).



316

317 Fig. 1. The % relative abundance of bacterial species that were significantly altered between pre-
 318 and post-supplementation. (A) *Neisseria subflava*, (B) *Actinomyces hyovaginalis* and (C)
 319 *Prevotella melaninogenica*. * denotes significant change from baseline ($P < 0.05$). Only within
 320 condition differences are shown for clarity.

321


322

323

324 **3.2. Impact of 7 days of NO₃⁻ supplementation on salivary pH, NO metabolites, and**
325 **blood pressure**

326 **3.2.1. Salivary pH**

327 There was a significant arm*time interaction for salivary pH ($P = 0.022$). There were no
328 differences in salivary pH at baseline (day 0) between the supplementation arms ($P >$
329 0.05). In the NO₃⁻ supplementation arm, salivary pH increased from baseline ($P = 0.043$,
330 95% CI 0.1 – 0.48) but did not change in the placebo arm ($P = 0.20$, Fig. 2). The post-
331 NO₃⁻ supplementation salivary pH was also higher than the equivalent value in the
332 placebo arm ($P = 0.05$, 95% CI 0.0 – 0.7).



333

334 Fig. 2. Salivary pH pre- and post-supplementation with NO₃⁻ and placebo. * denotes a significant
335 difference between measurement points ($P \leq 0.05$).

336

337 **3.3. Nitrate and nitrite levels in plasma and saliva**

338 There were no differences in baseline measurements of plasma and saliva NO metabolites
339 between the NO₃⁻ and placebo arms of the study (Table 2). Supplementation with NO₃⁻
340 increased salivary [NO₂⁻] ($P = 0.012$, 95% CI 263 – 1701 μ M), plasma [NO₂⁻] ($P = 0.01$,

341 95% CI 30 – 175 nM), salivary [NO₃⁻] ($P = 0.001$, 95% CI 3228 – 8694 μM) and plasma
342 [NO₃⁻] ($P < 0.001$, 95% CI 90 – 208 μM). In the placebo arm of the study, none of the
343 metabolites changed from baseline (all $P > 0.05$). The post-supplementation levels of
344 salivary NO₃⁻, plasma NO₃⁻, and salivary NO₂⁻ were higher in the NO₃⁻ arm compared to
345 the placebo (all $P < 0.001$). Conversely, the post-supplementation levels of plasma NO₂⁻
346 did not differ between supplementation arms ($P > 0.05$).

347

348 **3.4. Blood Pressure, flow mediated dilation, and resting heart rate**

349 There were no differences in SBP, DBP, MAP, flow mediated dilation, or resting heart
350 rate between supplementation arms at baseline (all $P > 0.05$, Table 3). There was a main
351 effect of study arm on MAP, but further interrogation with *post hoc* analyses revealed no
352 differences between study arms at either measurement point. None of the cardiovascular
353 variables were altered following supplementation with either NO₃⁻ or placebo (all $P >$
354 0.05).

355


356 **3.5. Acute nitrate response test**

357 **3.5.1. Nitrate and nitrite metabolism**

358 The levels of NO metabolites in the saliva and plasma are presented in Figure 3. For
359 salivary [NO₂⁻] and [NO₃⁻] there was a main effect of ‘time’ (all $P \leq 0.01$), ‘measurement’
360 (all $P \leq 0.002$) and a ‘time * measurement’ interaction (all $P \leq 0.015$). Salivary [NO₂⁻]
361 increased following the acute administration of NO₃⁻ in both the pre-supplementation
362 (day 0) ($P = 0.002$, 95% CI 968 - 3331 μM) and post-supplementation (day 8) acute
363 response tests ($P = 0.043$, 95% CI 50 – 2582 μM). Likewise, salivary NO₃⁻ was
364 significantly elevated in the acute tests on day 0 ($P < 0.001$, 95% CI 7107 – 16725 μM)
365 and day 8 ($P = 0.039$, 95% CI 400 – 13262 μM). The magnitude of the increase in both
366 salivary [NO₂⁻] and [NO₃⁻] was similar on days 0 and 8 (both $P > 0.05$). There were
367 significant main effects of ‘time’ ($P < 0.001$), ‘measurement’ ($P < 0.001$), and a ‘time x
368 measurement’ interaction ($P = 0.001$) on plasma [NO₃⁻]. For plasma [NO₂⁻], only the
369 ‘measurement’ main effect was significant ($P = 0.01$). Plasma [NO₂⁻] and [NO₃⁻]
370 increased in the acute response tests on both day 0 (NO₂⁻ $P < 0.001$, 95% CI 214 – 415

371 nM, NO_3^- $P < 0.001$, 278 – 428 μM) and day 8 (NO_2^- $P = 0.004$, 95% CI 72 - 275 nM,
 372 NO_3^- $P < 0.001$, 95% CI 220 – 337 μM). The magnitude of the increase in both plasma
 373 $[\text{NO}_2^-]$ and $[\text{NO}_3^-]$ was similar on each day (both $P > 0.05$).

374



375

376 Fig. 3. Salivary and plasma nitrate and nitrite concentration measured at baseline (day 0),
 377 following the acute administration of nitrate (day 0), after 7 days of nitrate supplementation (day
 378 8), and following further acute administration of nitrate (day 8). In the acute response
 379 measurements, saliva and plasma were measured 1.5 h and 2.5 h, respectively, after the ingestion
 380 of nitrate-rich beetroot juice. (A) Salivary NO_2^- , (B) plasma NO_2^- , (C) salivary NO_3^- , and (D)
 381 plasma NO_3^- . * denotes significant change from baseline ($P < 0.05$).


382

383 3.5.2. Blood pressure

384 BP data in the acute response tests are presented in Figure 4. There was a significant main
 385 effect of ‘measurement’ on SBP ($P = 0.004$) but no ‘time’ effect or ‘time * measurement’
 386 interaction. SBP was significantly reduced from baseline in the acute NO_3^- response test

387 on day 0 ($P = 0.05$, 95% CI 0 – 4 mmHg) and on day 8 ($P = 0.031$, 95% CI 0 – 6 mmHg,
388 Fig. 5). The magnitude of the decline in SBP did not differ between days 0 and 8 ($P >$
389 0.05). DBP and MAP did not differ between any measurements (all $P > 0.05$).

390




391

392 Fig.4. Blood pressure measured at baseline (day 0), following the acute administration of nitrate
393 (day 0), after 7 days of nitrate supplementation (day 8), and following further acute administration
394 of nitrate (day 8). In the acute response measurements blood pressure was measured 2.5 h after
395 the ingestion of nitrate-rich beetroot juice. (A) Systolic blood pressure, (B) Diastolic blood
396 pressure, (C) Mean arterial blood pressure. * denotes significant change from baseline ($P < 0.05$).

397 3.5.3. Flow Mediated Dilation

398 There was a significant main effect of ‘measurement’ on FMD % ($P = 0.021$). The FMD
399 response increased from baseline in the acute NO_3^- response tests on both day 0 ($P =$
400 0.014 , 95% CI 0.5% – 3.2%) and day 8 ($P = 0.042$, 95% CI 0.1% – 3.8%, Fig.5). The
401 magnitude of the FMD response was similar between days 0 and day 8 ($P > 0.05$). The
402 acute administration of NO_3^- did not alter the baseline or peak diameter of the brachial
403 artery (all $P > 0.05$).

404



405

406 Fig. 5. The flow mediated dilation response measured at baseline (day 0), following the acute
407 administration of nitrate (day 0), after 7 days of nitrate supplementation (day 8), and following
408 further acute administration of nitrate (day 8). In the acute response measurements flow mediated
409 dilation was measured 2.5 h after the ingestion of nitrate-rich beetroot juice. * denotes significant
410 change from baseline ($P < 0.05$).

411

412

413

414

415 4. Discussion

416 This study demonstrates that, as expected, 7 days of dietary NO₃⁻ supplementation in
417 healthy adults increases the levels of circulating NO metabolites and alters the abundance
418 of oral bacteria that have been previously implicated in the enterosalivary NO₃⁻-NO₂⁻-NO
419 pathway. Importantly, the magnitude of the change we observed in the altered bacterial
420 populations exceeds that of the typical biological variation [35] suggesting dietary NO₃⁻
421 supplementation results in meaningful alterations to the oral microbiome. Contrary to our
422 hypothesis, however, the adaptations to the oral environment did not enhance the plasma
423 and salivary responses to a NO₃⁻ dose. Furthermore, whilst the ingestion of NO₃⁻-rich
424 beetroot juice transiently increased the FMD response and reduced SBP in the hours
425 immediately following a NO₃⁻ dose, these effects were not augmented following a period
426 of chronic supplementation and had dissipated 10 h following the final NO₃⁻ dose. These
427 data suggest that frequent daily doses of NO₃⁻ would be necessary to result in a sustained
428 reduction in BP, at least in this healthy population.

429

430 4.1. Impact of 7 days of nitrate supplementation on tongue bacteria and salivary pH

431 Our samples had a high number of sequences (964,418) with a median of 21918
432 sequences per sample indicating that our sequencing coverage was at a sufficient depth
433 to detect meaningful changes in the dataset. This is further confirmed by the high Shannon
434 diversity index of 6.2 ± 0.6 and observed OTU value of 337 ± 81 . In concordance with
435 previous findings [30], NO₃⁻ supplementation did not change the Alpha diversity metric
436 demonstrating that this dietary intervention does not alter the community evenness of
437 bacterial species. However, 7 days of NO₃⁻ supplementation doubled the abundance of
438 the phylum Proteobacteria. These changes were predominantly due to an increase in the
439 abundance of the genus *Neisseria* and specifically the species *Neisseria subflava*.

440

441 Salivary pH increased in ten out of our eleven participants (from 7.13 ± 0.54 to $7.39 \pm$
442 0.68) following dietary supplementation with NO₃⁻. These data are in agreement with
443 previous work [36] which found that regular ingestion of beetroot juice increased salivary
444 pH from 7.0 to 7.5. We show further that supplementation with NO₃⁻-rich beetroot juice

445 reduced the abundance of *Prevotella melaninogenica*, an acidogenic species of bacteria
446 which thrive in environments with a pH between 5.5 and 6 and are thought to contribute
447 to dental caries [37,38]. This species are suggested to be important to NO_3^- reduction by
448 some [3] but not others [39]. One week of NO_3^- supplementation also reduced the
449 abundance of the genera *Streptococcus* and *Actinomyces* and the species *Actinomyces*
450 *hyovaginalis*. In support of these findings, Doel and colleagues [40] observed lower
451 counts of *Streptococcus mutans* in children with higher levels of NO_3^- and NO_2^- in their
452 saliva. While we did not detect this particular species in any of our samples, this is not
453 unusual in a healthy mouth [41]. Of note, both *Prevotella melaninogenica* and
454 *Streptococcus mutans* have been detected in atherosclerotic plaques and diseased heart
455 valve tissue suggesting these species may also be involved in the pathogenesis of
456 cardiovascular disease [42,43], whilst *Actinomyces* species can produce organic acid
457 leading to the accumulation of intracellular polysaccharides causing dysbiosis in the
458 biofilm leading to caries [44].

459

460 *Prevotella* was recently identified as the most abundant species in periodontal plaque
461 samples followed by *Streptococcus*, with *Actinomyces* identified as the fourth most
462 abundant and it is suggested that these bacteria are involved in the pathogenesis of oral
463 disease [45]. The reduction in the abundance of *Prevotella*, *Actinomyces*, and
464 *Streptococci* are likely due to the antimicrobial effects arising from elevated salivary NO_2^-
465 levels. Studies conducted *in-vitro* have shown that NO formed from NO_2^- can exert
466 bactericidal effects [46,47]. When present in the mouth, these pathogenic species of
467 bacteria ferment carbohydrates from the diet with strong acids produced as bi-products
468 [47]. A reduction in the number of these bacteria, therefore, will reduce the amount of
469 acid in the mouth and increase the pH of the saliva. These findings are important given
470 that a salivary pH sustained below 5.5 will result in de-mineralisation of the teeth [48]
471 and oral acidosis and acidogenic bacteria are the primary drivers behind dental caries and
472 periodontitis [49].

473

474 Dietary NO_3^- supplementation also increased the abundance of *Neisseria subflava* on the
475 tongue. This species of bacteria are able to use oxidised nitrogen compounds as

476 alternative electron acceptors for energy production [50] and can reduce NO_3^- in the
477 mouth [3]. *Neisseria subflava* are generally considered to be non-pathogenic and are
478 associated with good oral health [51]. *Neisseria subflava* favour a pH of between 7 – 7.5
479 and this species will replicate via binary fission when conditions and resources are
480 optimal [51,52]. The increase in salivary pH resulting from the ingestion of NO_3^- -rich
481 beetroot juice coupled with the concomitant reduction of other species within the oral
482 community, likely created an optimal environment for *Neisseria subflava* to propagate.

483

484 While the main outcomes of this study are broadly in agreement with two previous studies
485 [29,30], there are some notable differences. Firstly, both of the earlier studies reported that
486 NO_3^- -rich beetroot juice supplementation increased the abundance of *Rothia*
487 *mucilaginosa*. Secondly, Vanhatalo and colleagues [29] reported that NO_3^-
488 supplementation reduced the relative abundance of *Veillonella* whereas we did not. We
489 did, however, observe significant reductions in *Actinomyces* and *Streptococcus*. Although
490 the reasons for these conflicting findings are unclear, inter-individual differences between
491 participants and variations in oral bacteria sampling methodologies provide the most
492 likely explanations. Participants in the present study were a heterogeneous group of
493 healthy males (age 21 – 44 years). The earlier studies used hypercholesteremia patients
494 [29] or separate groups of younger (age 18-22 years) and older (70 – 79 years) adults [30].
495 Furthermore, both previous studies analysed the abundance of bacteria in saliva samples
496 whereas we collected bacteria directly from the tongue dorsum. While saliva samples will
497 likely provide a more representative composition of bacteria from all areas of the mouth,
498 the dorsal surface of the tongue has been shown to have the highest NO_3^- reduction
499 capacity of all oral sites [39]. The deep clefts of the tongue provide a protective and stable
500 anaerobic environment that is more conducive to the production of biofilms where
501 bacterial NO_3^- reduction can easily occur [2]. In addition, the bacteria in saliva include
502 those shed from biofilms [53] which may be less metabolically active than those found
503 on the tongue [13]. Given that we aimed to relate bacterial presence to NO_3^- -reduction
504 capacity it was considered more appropriate to sample the tongue in this instance.

505

506 An unexpected finding of the study was the increase in the abundance of *Neisseria*
507 *subflava* following ingestion of the placebo, albeit to a lesser extent than in the NO_3^-
508 supplementation arm. This is all the more surprising given there was a small but non-
509 significant reduction in salivary pH after 7 days of NO_3^- -depleted beetroot juice (from
510 7.22 ± 0.61 to 6.99 ± 1.00); an environment which may be expected to suppress *Neisseria*
511 *subflava*. Of note is that both NO_3^- -rich and NO_3^- -depleted versions of the beetroot juice
512 contained a considerable amount of sugar (~15g total carbohydrate per 70 ml bottle). In
513 the absence of an elevation in salivary NO_2^- , cariogenic bacteria will increase acid
514 production in response to an increased availability of carbohydrate. However, beetroot
515 juice also has a high total antioxidant capacity and polyphenol content and is rich in
516 several compounds including phenolic acids, flavonoids, and betalains [54]. It is possible
517 that that *Neisseria subflava* responded positively to some of these components although
518 the effects are clearly augmented by NO_3^- . Conversely, a previous study [29] did not
519 report alterations to the oral microbiome after placebo. It is not possible to elucidate
520 whether the placebo altered the microbiome of participants in similar work [30] as
521 samples were not collected at baseline. While our data require corroboration, they do
522 suggest that the NO_3^- -depleted beetroot juice is not completely inert; a point that should
523 be carefully considered by researchers during study design.

524

525 ***4.2. Consequences of changes in the oral microbiome on nitrate and nitrite levels***

526 Recent work [30] showed that individuals with a high abundance of *Prevotella*
527 *melaninogenica* and *Campylobacter concisus* on the tongue at baseline had less NO_2^- in
528 the plasma and smaller reductions in BP in response to chronic NO_3^- supplementation.
529 The authors suggested that the NO_2^- reduction genes encoded by these bacteria impair
530 downstream NO_2^- accumulation via bacterial reduction of NO_2^- in the oral cavity before
531 it enters the circulation. In the present study, seven days of NO_3^- supplementation reduced
532 the abundance of *Prevotella melaninogenica* and increased *Neisseria subflava*. As
533 expected, both saliva and plasma NO_2^- were elevated from baseline in the NO_3^- arm of the
534 study. However, it is not possible to isolate the influence of the altered microbiome on
535 basal levels of NO_2^- as these parameters were almost certainly increased directly by the
536 ingestion of beetroot juice on the previous day. Nevertheless, previous data from our

537 laboratory has demonstrated that the capacity to generate NO_2^- in the mouth is associated
538 with the abundance of NO_3^- -reducing bacteria on the tongue [20]. As a consequence, we
539 also expected that saliva and plasma NO_2^- levels would be augmented post- NO_3^-
540 supplementation following ingestion of a NO_3^- -rich beetroot juice bolus. Data from the
541 acute response component of this study, however, provides evidence to the contrary.
542 Firstly; the peak levels of saliva and plasma in response to the beetroot juice bolus were
543 similar before and after the NO_3^- supplementation period. This is particularly intriguing
544 given baseline levels were elevated in the post-supplementation test. This suggests that
545 when “excess” NO_2^- is produced it is excreted, perhaps to avoid excessive drops in BP.
546 Secondly; the magnitude of increase in salivary NO_2^- during the acute response test did
547 not change following 7 days of NO_3^- supplementation. The lack of changes to NO_2^-
548 generation may be due to the fact that *Prevotella* and *Actinomyces*, although antagonistic
549 to oral health, have also been identified as important to NO_3^- reduction either directly or
550 through bacterial community interactions [3]. Therefore, an increase in the abundance of
551 one species of bacteria thought to be important to the NO_3^- reduction process (*Neisseria*
552 *subflava*) has been offset by reductions in others. An enhanced reduction of NO_2^- to NO
553 in the oral cavity to prevent accumulation of NO_2^- in the saliva [30] seems unlikely in this
554 instance as the abundance of these bacterial species were not altered by NO_3^-
555 supplementation. Furthermore, NO_2^- reduction is a slow reaction and it is questionable
556 whether there would be time for this to occur in the open in vivo salivary system [55].

557

558 It should also be acknowledged that the participants in the present study were all in good
559 oral health meaning their oral microbiome was already capable of efficient NO_3^-
560 reduction. Alternatively, there may be other rate limiting steps in the NO_3^- reduction
561 process including gastric emptying and absorption rates, the availability of sialin (NO_3^-
562 transporter in saliva), and salivary flow rates. Further mechanistic insight would also be
563 provided by a direct test of NO_3^- reduction in the mouth, metatranscriptomic analysis to
564 determine NO_2^- and NO_3^- reductase gene expression of the oral bacteria and collecting
565 data from patients with oral diseases such as periodontitis.

566

567

568 *4.3. Consequences of changes in the oral microbiome on vascular function*

569 In the present study, there was a transient reduction in SBP and increase in the FMD
570 response during the acute NO_3^- response tests before and after NO_3^- supplementation.
571 These effects were likely mediated by the increased production of NO resulting in
572 vasodilation [56]. Likewise, it has been previously observed that SBP was similarly
573 reduced after acute (2.5 h after ingestion) and chronic (15 d) supplementation with
574 beetroot juice [57]. Our data extends these findings and demonstrates that adaptations to
575 the oral microbiome arising from sustained NO_3^- supplementation did not in this instance
576 alter vascular responsiveness to a NO_3^- dose. This is not surprising given that the increase
577 in plasma $[\text{NO}_2^-]$ was not augmented in the post-supplementation acute response test. It
578 should be noted, however, that our participants were a group of normotensive healthy
579 volunteers and results may be different in populations with compromised vascular
580 responsiveness.

581

582 It should be highlighted that SBP was only reduced during the acute NO_3^- response tests
583 but not following 7 days of NO_3^- supplementation. This was likely due to the 10 h gap
584 between the ingestion of the last NO_3^- dose and the collection of measurements on day 8.
585 While plasma NO_2^- was elevated from baseline, the magnitude of this increase was small
586 (102 nM) and was seemingly insufficient to reduce BP in this healthy population.
587 Therefore, larger or more frequent doses of NO_3^- may be needed to elicit sustained
588 improvements in vascular function.

589

590 **5. Conclusions**

591 Seven days of supplementation with NO_3^- -rich beetroot juice significantly increased the
592 levels of circulating NO metabolites, increased the pH of saliva, and caused meaningful
593 alterations to the oral microbiome in favour of oral health. These data are significant given
594 that a high abundance of pathogenic bacteria can cause periodontitis and sustained oral
595 acidosis will result in dental caries. For the first time, our data shows that the
596 aforementioned adaptations to the oral microbiome do not alter the capacity to produce
597 salivary NO_2^- or enhance vascular responsiveness following a dose of beetroot juice, at
598 least in a healthy adult population.

599 **Additional Information**

600 ***Competing Interests***

601 The authors declare that they have no competing interests.

602

603 ***Author Contributions***

604 The study was conceived by MB and CE and all authors contributed towards the
605 experimental design. Data were collected by MB, LL, CM, NS, and CE. Analysis of FMD
606 data were performed by MB and NS. Analysis of plasma and saliva samples were
607 performed by MB, LL, and CM. Bacterial samples were prepared for analyses by MB and
608 JB. Bioinformatical analysis of bacteria were performed by MB. Statistical analyses were
609 completed by MB and CE. MB prepared the first draft of the manuscript. All authors have
610 critically revised and approved the final version of the manuscript submitted for
611 publication.

612

613 ***Funding***

614 This project was funded by a grant from the Hannah Dairy Research Foundation. Dr
615 David Muggeridge is supported by the European Union's INTERREG VA Programme,
616 managed by the Special EU Programmes Body (SEUPB).

617

618

619 **Table 1:** Pre- and post-supplementation bacterial diversity metrics and relative abundance
 620 of the bacteria that were altered by dietary nitrate supplementation.

Diversity Metric	Time (Day)	Nitrate	Placebo	ANOVA (<i>P</i> Value)
Shannon Diversity Index	Pre (0)	6.3 ± 0.6	5.9 ± 0.7	Time = 0.707
	Post (8)	6 ± 0.9	6.6 ± 0.3	Arm = 0.858 Interaction = 0.122
Observed OTUs	Pre (0)	312 ± 89	349 ± 97	Time = 0.876
	Post (8)	383 ± 56	304 ± 83	Arm = 0.856 Interaction = 0.07
Bacteria				
<i>Prevotella</i> (% relative abundance)	Pre (0)	34 ± 17	26 ± 16	Time = 0.283
	Post (8)	23 ± 11*†	31 ± 14	Arm = 0.993 Interaction = 0.053
<i>Neisseria</i> (% relative abundance)	Pre (0)	2 ± 3	1 ± 1	Time = 0.001
	Post (8)	9 ± 5*†	4 ± 3*	Arm < 0.001 Interaction = 0.008
<i>Streptococcus</i> (% relative abundance)	Pre (0)	9 ± 6	6 ± 4	Time = 0.404
	Post (8)	6 ± 4*†	8 ± 3	Arm = 0.816 Interaction = 0.006
<i>Actinomyces</i> (% relative abundance)	Pre (0)	1.1 ± 0.7	0.9 ± 0.6	Time = 0.376
	Post (8)	0.5 ± 0.4*†	0.7 ± 0.2	Arm = 0.014 Interaction = 0.164

621 * denotes a significant difference from the pre-supplementation (day 0).

622 † denotes a greater change from the pre-supplementation value compared to the placebo arm.

623

624 **Table 2:** Levels of nitric oxide metabolites pre- and post-supplementation in each study arm.

Parameter	Time (Day)	Nitrate	Placebo	ANOVA (<i>P</i> Value)
Plasma nitrite (nM)	Pre (0)	150 ± 84	174 ± 111	Time = 0.001
	Post (8)	252 ± 165*	220 ± 112	Arm = 0.898 Interaction = 0.290
Plasma nitrate (µM)	Pre (0)	52 ± 24	69 ± 64	Time < 0.001
	Post (8)	201 ± 104*†	57 ± 36	Arm < 0.001 Interaction = 0.001
Salivary nitrite (µM)	Pre (0)	415 ± 420	365 ± 301	Time = 0.01
	Post (8)	1397 ± 1151*†	367 ± 297	Arm = 0.002 Interaction = 0.015
Salivary nitrate (µM)	Pre (0)	810 ± 404	746 ± 388	Time = 0.001
	Post (8)	6801 ± 3956*†	875 ± 589	Arm < 0.001 Interaction = 0.001

625 * denotes a significant difference from the pre-supplementation (day 0).

626 † denotes a greater change from the pre-supplementation value compared to the placebo arm.

627

628

629 **Table 3:** Cardiovascular variables pre- and post-supplementation in each study arm.

Parameter	Time (Day)	Nitrate	Placebo	ANOVA (<i>P</i> Value)
Systolic blood pressure (mmHg)	Pre (0)	122 ± 10	124 ± 6	Time = 0.196
	Post (8)	122 ± 6	127 ± 8	Arm = 0.325 Interaction = 0.290
Diastolic blood pressure (mmHg)	Pre (0)	67 ± 7	68 ± 7	Time = 0.141
	Post (8)	66 ± 5	65 ± 6	Arm = 0.771 Interaction = 0.215
Mean arterial pressure (mmHg)	Pre (0)	85 ± 8	89 ± 6	Time = 0.311
	Post (8)	86 ± 5	91 ± 6	Arm = 0.043 Interaction = 0.581
Resting heart rate (beat·min ⁻¹)	Pre (0)	55 ± 7	55 ± 5	Time = 0.973
	Post (8)	56 ± 8	55 ± 6	Arm = 0.631 Interaction = 0.459
Flow mediated dilation (%)	Pre (0)	10.46 ± 3.76	12.1 ± 5.25	Time = 0.021
	Post (8)	12.03 ± 5.09	14.05 ± 6.18	Arm = 0.221 Interaction = 0.854

630

631


632 **References**

- 633 [1] M. Mazidi, P. Rezaie, A.P. Kengne, M.G. Mobarhan, G.A. Ferns, Gut microbiome and
634 metabolic syndrome, *Diabetes Metab. Syndr.* 10 (2016) S150-157.
635 doi:10.1016/j.dsx.2016.01.024.
- 636 [2] J.J. Doel, N. Benjamin, M.P. Hector, M. Rogers, R.P. Allaker, Evaluation of bacterial nitrate
637 reduction in the human oral cavity, *Eur. J. Oral Sci.* 113 (2005) 14–19. doi:10.1111/j.1600-
638 0722.2004.00184.x.
- 639 [3] E.R. Hyde, F. Andrade, Z. Vaksman, K. Parthasarathy, H. Jiang, D.K. Parthasarathy, A.C.
640 Torregrossa, G. Tribble, H.B. Kaplan, J.F. Petrosino, N.S. Bryan, Metagenomic Analysis of
641 Nitrate-Reducing Bacteria in the Oral Cavity: Implications for Nitric Oxide Homeostasis,
642 *PLoS ONE.* 9 (2014) e88645. doi:10.1371/journal.pone.0088645.
- 643 [4] J.O. Lundberg, E. Weitzberg, M.T. Gladwin, The nitrate-nitrite-nitric oxide pathway in
644 physiology and therapeutics, *Nat. Rev. Drug Discov.* 7 (2008) 156–167.
645 doi:10.1038/nrd2466.
- 646 [5] J. Petersson, M. Phillipson, E.Å. Jansson, A. Patzak, J.O. Lundberg, L. Holm, Dietary nitrate
647 increases gastric mucosal blood flow and mucosal defense, *Am. J. Physiol. - Gastrointest.*
648 *Liver Physiol.* 292 (2007) G718–G724. doi:10.1152/ajpgi.00435.2006.
- 649 [6] P. Kleinbongard, A. Dejam, T. Lauer, T. Jax, S. Kerber, P. Gharini, J. Balzer, R.B. Zotz, R.E.
650 Scharf, R. Willers, A.N. Schechter, M. Feelisch, M. Kelm, Plasma nitrite concentrations
651 reflect the degree of endothelial dysfunction in humans, *Free Radic. Biol. Med.* 40 (2006)
652 295–302. doi:10.1016/j.freeradbiomed.2005.08.025.
- 653 [7] Z. Xiyuan, R.H.A. Fink, M. Mosqueira, NO-sGC Pathway Modulates Ca²⁺Release and
654 Muscle Contraction in Zebrafish Skeletal Muscle, *Front. Physiol.* 8 (2017) 607.
655 doi:10.3389/fphys.2017.00607.
- 656 [8] E.L. Wightman, C.F. Haskell-Ramsay, K.G. Thompson, J.R. Blackwell, P.G. Winyard, J.
657 Forster, A.M. Jones, D.O. Kennedy, Dietary nitrate modulates cerebral blood flow
658 parameters and cognitive performance in humans: A double-blind, placebo-controlled,
659 crossover investigation, *Physiol. Behav.* 149 (2015) 149–158.
660 doi:10.1016/j.physbeh.2015.05.035.
- 661 [9] Z. Bahadoran, A. Ghasemi, P. Mirmiran, F. Azizi, F. Hadaegh, Beneficial effects of
662 inorganic nitrate/nitrite in type 2 diabetes and its complications, *Nutr. Metab.* 12 (2015)
663 16. doi:10.1186/s12986-015-0013-6.
- 664 [10] F.J. Larsen, T.A. Schiffer, S. Borniquel, K. Sahlin, B. Ekblom, J.O. Lundberg, E. Weitzberg,
665 Dietary Inorganic Nitrate Improves Mitochondrial Efficiency in Humans, *Cell Metab.* 13
666 (2011) 149–159. doi:10.1016/j.cmet.2011.01.004.
- 667 [11] N.G. Hord, Y. Tang, N.S. Bryan, Food sources of nitrates and nitrites: the physiologic
668 context for potential health benefits, *Am. J. Clin. Nutr.* 90 (2009) 1–10.
669 doi:10.3945/ajcn.2008.27131.
- 670 [12] L. Qin, X. Liu, Q. Sun, Z. Fan, D. Xia, G. Ding, H.L. Ong, D. Adams, W.A. Gahl, C. Zheng, S.
671 Qi, L. Jin, C. Zhang, L. Gu, J. He, D. Deng, I.S. Ambudkar, S. Wang, Sialin (SLC17A5)
672 functions as a nitrate transporter in the plasma membrane, *Proc. Natl. Acad. Sci. U. S. A.*
673 109 (2012) 13434–13439. doi:10.1073/pnas.1116633109.
- 674 [13] C. Williams, K.E.L. McCOLL, Review article: proton pump inhibitors and bacterial
675 overgrowth, *Aliment. Pharmacol. Ther.* 23 (2005) 3–10. doi:10.1111/j.1365-
676 2036.2006.02707.x.
- 677 [14] V. Kapil, S.M.A. Haydar, V. Pearl, J.O. Lundberg, E. Weitzberg, A. Ahluwalia, Physiological
678 role for nitrate-reducing oral bacteria in blood pressure control, *Free Radic. Biol. Med.* 55
679 (2013) 93–100. doi:10.1016/j.freeradbiomed.2012.11.013.

- 680 [15] T.M. Millar, C.R. Stevens, N. Benjamin, R. Eisenthal, R. Harrison, D.R. Blake, Xanthine
681 oxidoreductase catalyses the reduction of nitrates and nitrite to nitric oxide under
682 hypoxic conditions, *FEBS Lett.* 427 (1998) 225–228.
- 683 [16] D.J. Muggeridge, C.C.F. Howe, O. Spendiff, C. Pedlar, P.E. James, C. Easton, A single dose
684 of beetroot juice enhances cycling performance in simulated altitude, *Med. Sci. Sports
685 Exerc.* 46 (2014) 143–150. doi:10.1249/MSS.0b013e3182a1dc51.
- 686 [17] V. Kapil, R.S. Khambata, A. Robertson, M.J. Caulfield, A. Ahluwalia, Dietary nitrate
687 provides sustained blood pressure lowering in hypertensive patients: a randomized,
688 phase 2, double-blind, placebo-controlled study, *Hypertension.* 65 (2015) 320–327.
689 doi:10.1161/HYPERTENSIONAHA.114.04675.
- 690 [18] A.J. Webb, N. Patel, S. Loukogeorgakis, M. Okorie, Z. Aboud, S. Misra, R. Rashid, P. Miall,
691 J. Deanfield, N. Benjamin, R. MacAllister, A.J. Hobbs, A. Ahluwalia, Acute Blood Pressure
692 Lowering, Vasoprotective, and Antiplatelet Properties of Dietary Nitrate via
693 Bioconversion to Nitrite, *Hypertension.* 51 (2008) 784–790.
694 doi:10.1161/HYPERTENSIONAHA.107.103523.
- 695 [19] N.F. McMahon, M.D. Leveritt, T.G. Pavey, The Effect of Dietary Nitrate Supplementation
696 on Endurance Exercise Performance in Healthy Adults: A Systematic Review and Meta-
697 Analysis, *Sports Med. Auckl. NZ.* 47 (2017) 735–756. doi:10.1007/s40279-016-0617-7.
- 698 [20] M.C. Burleigh, L. Liddle, C. Monaghan, D.J. Muggeridge, N. Sculthorpe, J.P. Butcher, F.L.
699 Henriquez, J.D. Allen, C. Easton, Salivary nitrite production is elevated in individuals with
700 a higher abundance of oral nitrate-reducing bacteria, *Free Radic. Biol. Med.* 120 (2018)
701 80–88. doi:10.1016/j.freeradbiomed.2018.03.023.
- 702 [21] C.P. Bondonno, A.H. Liu, K.D. Croft, M.J. Consideine, I.B. Puddey, R.J. Woodman, J.M.
703 Hodgson, Antibacterial mouthwash blunts oral nitrate reduction and increases blood
704 pressure in treated hypertensive men and women, *Am. J. Hypertens.* 28 (2015) 572–575.
705 doi:10.1093/ajh/hpu192.
- 706 [22] M. Woessner, J.M. Smoliga, B. Tarzia, T. Stabler, M. Van Bruggen, J.D. Allen, A stepwise
707 reduction in plasma and salivary nitrite with increasing strengths of mouthwash following
708 a dietary nitrate load, *Nitric Oxide.* 54 (2016) 1–7. doi:10.1016/j.niox.2016.01.002.
- 709 [23] C. Easton, C. Monaghan, L. Liddle, L. McIlvenna, M. Burleigh, D.J. Muggeridge, B.O.
710 Fernandez, M. Feelisch, Anti-Bacterial Mouthwash Reduces Plasma Nitrite Following
711 Dietary Nitrate Supplementation but Does Not Alter Stress Response: 2829 Board #349
712 June 2 930 AM - 1100 AM, *Med. Sci. Sports Exerc.* 49 (2017) 816.
713 doi:10.1249/01.mss.0000519186.30559.86.
- 714 [24] J.A. Aas, B.J. Paster, L.N. Stokes, I. Olsen, F.E. Dewhirst, Defining the Normal Bacterial
715 Flora of the Oral Cavity, *J. Clin. Microbiol.* 43 (2005) 5721–5732.
716 doi:10.1128/JCM.43.11.5721-5732.2005.
- 717 [25] R.G. Abisado, S. Benomar, J.R. Klaus, A.A. Dandekar, J.R. Chandler, Bacterial Quorum
718 Sensing and Microbial Community Interactions, *MBio.* 9 (2018) e02331-17.
719 doi:10.1128/mBio.02331-17.
- 720 [26] Z. Li, S.K. Nair, Quorum sensing: How bacteria can coordinate activity and synchronize
721 their response to external signals?, *Protein Sci.* 21 (2012) 1403–1417.
722 doi:10.1002/pro.2132.
- 723 [27] S. Majumdar, S. Pal, Cross- species communication in bacterial world, *J. Cell Commun.
724 Signal.* 11 (2017) 187–190. doi:10.1007/s12079-017-0383-9.
- 725 [28] E.R. Hyde, B. Luk, S. Cron, L. Kusic, T. McCue, T. Bauch, H. Kaplan, G. Tribble, J.F.
726 Petrosino, N.S. Bryan, Characterization of the rat oral microbiome and the effects of
727 dietary nitrate, *Free Radic. Biol. Med.* 77 (2014) 249–257.
728 doi:10.1016/j.freeradbiomed.2014.09.017.

- 729 [29] S. Velmurugan, J.M. Gan, K.S. Rathod, R.S. Khambata, S.M. Ghosh, A. Hartley, S. Van Eijl,
730 V. Sagi-Kiss, T.A. Chowdhury, M. Curtis, G.G.C. Kuhnle, W.G. Wade, A. Ahluwalia, Dietary
731 nitrate improves vascular function in patients with hypercholesterolemia: a randomized,
732 double-blind, placebo-controlled study, *Am. J. Clin. Nutr.* 103 (2016) 25–38.
733 doi:10.3945/ajcn.115.116244.
- 734 [30] A. Vanhatalo, J.R. Blackwell, J.E. L'Heureux, D.W. Williams, A. Smith, M. van der Giezen,
735 P.G. Winyard, J. Kelly, A.M. Jones, Nitrate-responsive oral microbiome modulates nitric
736 oxide homeostasis and blood pressure in humans, *Free Radic. Biol. Med.* 124 (2018) 21–
737 30. doi:10.1016/j.freeradbiomed.2018.05.078.
- 738 [31] P.D. Marsh, Are dental diseases examples of ecological catastrophes?, *Microbiology.* 149
739 (2003) 279–294. doi:10.1099/mic.0.26082-0.
- 740 [32] R.K. Singh, H.-W. Chang, D. Yan, K.M. Lee, D. Ucmak, K. Wong, M. Abrouk, B. Farahnik, M.
741 Nakamura, T.H. Zhu, T. Bhutani, W. Liao, Influence of diet on the gut microbiome and
742 implications for human health, *J. Transl. Med.* 15 (2017). doi:10.1186/s12967-017-1175-
743 y.
- 744 [33] L. Liddle, C. Monaghan, M.C. Burleigh, L.C. McIlvenna, D.J. Muggeridge, C. Easton,
745 Changes in body posture alter plasma nitrite but not nitrate concentration in humans,
746 *Nitric Oxide Biol. Chem.* 72 (2018) 59–65.
- 747 [34] J.G. Caporaso, J. Kuczynski, J. Stombaugh, K. Bittinger, F.D. Bushman, E.K. Costello, N.
748 Fierer, A.G. Peña, J.K. Goodrich, J.I. Gordon, G.A. Huttley, S.T. Kelley, D. Knights, J.E.
749 Koenig, R.E. Ley, C.A. Lozupone, D. McDonald, B.D. Muegge, M. Pirrung, J. Reeder, J.R.
750 Sevinsky, P.J. Turnbaugh, W.A. Walters, J. Widmann, T. Yatsunenko, J. Zaneveld, R.
751 Knight, QIIME allows analysis of high-throughput community sequencing data, *Nat.*
752 *Methods.* 7 (2010) 335. doi:10.1038/nmeth.f.303.
- 753 [35] L. Liddle, M.C. Burleigh, C. Monaghan, D.J. Muggeridge, N. Sculthorpe, C.R. Pedlar, J.
754 Butcher, F.L. Henriquez, C. Easton, Variability in nitrate-reducing oral bacteria and nitric
755 oxide metabolites in biological fluids following dietary nitrate administration: An
756 assessment of the critical difference, *Nitric Oxide.* 83 (2019) 1–10.
757 doi:10.1016/j.niox.2018.12.003.
- 758 [36] B. Hohensinn, R. Haselgrübler, U. Müller, V. Stadlbauer, P. Lanzerstorfer, G. Lirk, O.
759 Höglinger, J. Weghuber, Sustaining elevated levels of nitrite in the oral cavity through
760 consumption of nitrate-rich beetroot juice in young healthy adults reduces salivary pH,
761 *Nitric Oxide Biol. Chem.* 60 (2016) 10–15. doi:10.1016/j.niox.2016.08.006.
- 762 [37] N. Kianoush, C.J. Adler, K.-A.T. Nguyen, G.V. Browne, M. Simonian, N. Hunter, Bacterial
763 Profile of Dentine Caries and the Impact of pH on Bacterial Population Diversity, *PLoS*
764 *ONE.* 9 (2014). doi:10.1371/journal.pone.0092940.
- 765 [38] R.M. Braga, M.N. Dourado, W.L. Araújo, Microbial interactions: ecology in a molecular
766 perspective, *Braz. J. Microbiol.* 47 (2016) 86–98. doi:10.1016/j.bjm.2016.10.005.
- 767 [39] J.J. Doel, N. Benjamin, M.P. Hector, M. Rogers, R.P. Allaker, Evaluation of bacterial nitrate
768 reduction in the human oral cavity, *Eur. J. Oral Sci.* 113 (2005) 14–19. doi:10.1111/j.1600-
769 0722.2004.00184.x.
- 770 [40] J.J. Doel, M.P. Hector, C.V. Amirtham, L.A. Al-Anzan, N. Benjamin, R.P. Allaker, Protective
771 effect of salivary nitrate and microbial nitrate reductase activity against caries, *Eur. J.*
772 *Oral Sci.* 112 (2004) 424–428. doi:10.1111/j.1600-0722.2004.00153.x.
- 773 [41] E.L. Gross, C.J. Beall, S.R. Kutsch, N.D. Firestone, E.J. Leys, A.L. Griffen, Beyond
774 *Streptococcus mutans*: Dental Caries Onset Linked to Multiple Species by 16S rRNA
775 Community Analysis, *PLOS ONE.* 7 (2012) e47722. doi:10.1371/journal.pone.0047722.
- 776 [42] V.I. Haraszthy, J.J. Zambon, M. Trevisan, M. Zeid, R.J. Genco, Identification of periodontal
777 pathogens in atheromatous plaques, *J. Periodontol.* 71 (2000) 1554–1560.
778 doi:10.1902/jop.2000.71.10.1554.

- 779 [43] K. Nakano, H. Inaba, R. Nomura, H. Nemoto, M. Takeda, H. Yoshioka, H. Matsue, T.
780 Takahashi, K. Taniguchi, A. Amano, T. Ooshima, Detection of Cariogenic *Streptococcus*
781 *mutans* in Extirpated Heart Valve and Atheromatous Plaque Specimens, *J. Clin. Microbiol.*
782 44 (2006) 3313–3317. doi:10.1128/JCM.00377-06.
- 783 [44] J. Li, Y. Li, Y. Zhou, C. Wang, B. Wu, J. Wan, *Actinomyces* and Alimentary Tract Diseases: A
784 Review of Its Biological Functions and Pathology, *BioMed Res. Int.* 2018 (2018).
785 doi:10.1155/2018/3820215.
- 786 [45] P. Ye, D.W.S. Harty, C.C. Chapple, M.A. Nadkarni, A. a. D.E. Carlo, N. Hunter, *Streptococci*
787 and *Actinomyces* induce antibodies which cross react with epithelial antigens in
788 periodontitis, *Clin. Exp. Immunol.* 131 (2003) 468–476.
- 789 [46] L.S. Silva Mendez, R.P. Allaker, J.M. Hardie, N. Benjamin, Antimicrobial effect of acidified
790 nitrite on cariogenic bacteria, *Oral Microbiol. Immunol.* 14 (1999) 391–392.
- 791 [47] C.E. Radcliffe, N.C. Akram, F. Hurrell, D.B. Drucker, Effects of nitrite and nitrate on the
792 growth and acidogenicity of *Streptococcus mutans*, *J. Dent.* 30 (2002) 325–331.
- 793 [48] E.A. Abou Neel, A. Aljabo, A. Strange, S. Ibrahim, M. Coathup, A.M. Young, L. Bozec, V.
794 Mudera, Demineralization–remineralization dynamics in teeth and bone, *Int. J.*
795 *Nanomedicine.* 11 (2016) 4743–4763. doi:10.2147/IJN.S107624.
- 796 [49] C. Seethalakshmi, R.C.J. Reddy, N. Asifa, S. Prabhu, Correlation of Salivary pH, Incidence
797 of Dental Caries and Periodontal Status in Diabetes Mellitus Patients: A Cross-sectional
798 Study, *J. Clin. Diagn. Res. JCDR.* 10 (2016) ZC12–ZC14.
799 doi:10.7860/JCDR/2016/16310.7351.
- 800 [50] K.R. Barth, V.M. Isabella, V.L. Clark, Biochemical and genomic analysis of the
801 denitrification pathway within the genus *Neisseria*, *Microbiology.* 155 (2009) 4093.
802 doi:10.1099/mic.0.032961-0.
- 803 [51] T. Tønjum, J. van Putten, 179 - *Neisseria*, in: J. Cohen, W.G. Powderly, S.M. Opal (Eds.),
804 *Infect. Dis. Fourth Ed.*, Elsevier, 2017: pp. 1553-1564.e1. doi:10.1016/B978-0-7020-6285-
805 8.00179-9.
- 806 [52] W. Margolin, Binary Fission in Bacteria, in: *ELS*, American Cancer Society, 2014.
807 doi:10.1002/9780470015902.a0001420.pub2.
- 808 [53] B.T. Rosier, P.D. Marsh, A. Mira, Resilience of the Oral Microbiota in Health: Mechanisms
809 That Prevent Dysbiosis, *J. Dent. Res.* 97 (2018) 371–380.
810 doi:10.1177/0022034517742139.
- 811 [54] P.C. Wootton-Beard, K. Brandt, D. Fell, S. Warner, L. Ryan, Effects of a beetroot juice with
812 high neobetanin content on the early-phase insulin response in healthy volunteers, *J.*
813 *Nutr. Sci.* 3 (2014). doi:10.1017/jns.2014.7.
- 814 [55] E.R. Hyde, F. Andrade, Z. Vaksman, K. Parthasarathy, H. Jiang, D.K. Parthasarathy, A.C.
815 Torregrossa, G. Tribble, H.B. Kaplan, J.F. Petrosino, N.S. Bryan, Metagenomic analysis of
816 nitrate-reducing bacteria in the oral cavity: implications for nitric oxide homeostasis, *PLoS*
817 *One.* 9 (2014) e88645. doi:10.1371/journal.pone.0088645.
- 818 [56] A. Modin, H. Björne, M. Herulf, K. Alving, E. Weitzberg, J.O. Lundberg, Nitrite-derived
819 nitric oxide: a possible mediator of “acidic-metabolic” vasodilation, *Acta Physiol. Scand.*
820 171 (2001) 9–16. doi:10.1046/j.1365-201X.2001.00771.x.
- 821 [57] A. Vanhatalo, S.J. Bailey, J.R. Blackwell, F.J. DiMenna, T.G. Pavey, D.P. Wilkerson, N.
822 Benjamin, P.G. Winyard, A.M. Jones, Acute and chronic effects of dietary nitrate
823 supplementation on blood pressure and the physiological responses to moderate-
824 intensity and incremental exercise, *Am. J. Physiol.-Regul. Integr. Comp. Physiol.* 299
825 (2010) R1121–R1131. doi:10.1152/ajpregu.00206.2010.
- 826




827

828 *Supplementary Fig. 1* Bacterial species that made up > 1% of the dataset displayed in ascending order of abundance.
 829 *Prevotella melaninogenica* was the most abundant species. * indicates those which were significantly altered.

830

831



832

833 *Supplementary Fig. 2* The proportions of the five main phyla on the tongue dorsum at the four measurement time
 834 points, Pre nitrate, Post nitrate, Pre placebo, and Post placebo. * indicates a significant increase in Proteobacteria
 835 from Pre to Post nitrate.